Mineralys Therapeutics, Inc.

NasdaqGS:MLYS Stock Report

Market Cap: US$2.0b

Mineralys Therapeutics Management

Management criteria checks 3/4

Mineralys Therapeutics' CEO is Jon Congleton, appointed in Nov 2020, has a tenure of 5.58 years. total yearly compensation is $5.54M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 0.66% of the company’s shares, worth $13.12M. The average tenure of the management team and the board of directors is 3.4 years and 4.1 years respectively.

Key information

Jon Congleton

Chief executive officer

US$5.5m

Total compensation

CEO salary percentage11.48%
CEO tenure5.6yrs
CEO ownership0.7%
Management average tenure3.4yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Seeking Alpha • May 07

Mineralys: 'Hold' As Hypertension OSA Data Barely Delivers And AstraZeneca On The Move

Summary Mineralys is downgraded from 'Strong Buy' to 'Hold' due to competitive and clinical setbacks. MLYS's lorundrostat NDA was accepted by the FDA with a PDUFA date of December 22, 2026, targeting uncontrolled/resistant hypertension. Failure to meet the primary endpoint in the OSA hypertension subpopulation and AstraZeneca's earlier PDUFA for baxdrostat create significant headwinds. MLYS remains well-capitalized, with cash runway into 2028 and further ATM capacity, but faces execution and competitive risks. Read the full article on Seeking Alpha
New Narrative • Apr 02

Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains

Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 19

Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity

Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?
New Narrative • Mar 05

Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech

Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?
Analysis Article • Jun 14

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 10

Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts

Summary Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. The Anti-Hypertensive drugs market worldwide is expected to reach $22.41 billion by 2025. Read the full article on Seeking Alpha
Analysis Article • Feb 20

Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 20

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension

Summary I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company’s slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. My main concern with MLYS is its relatively short cash runway. But still, I think it has enough runway to fund its key trials through 2025. Overall, I feel MLYS is a good speculative “Buy” at these levels, especially after a substantial pullback in the shares with promising catalysts lined up in 2025. Read the full article on Seeking Alpha
Analysis Article • Oct 07

Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Sep 17

Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning

Summary Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move. Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices. Read the full article on Seeking Alpha
Analysis Article • Jun 06

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 18

Mineralys Therapeutics: A Story To Keep An Eye On

Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that has shown promising results in Phase 2 trials for the treatment of uncontrolled hypertension. Mineralys is conducting two additional trials for lorundrostat and is also evaluating its potential for the treatment of hypertension in patients with chronic kidney disease. A full investment analysis follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Feb 09

Mineralys: 2nd Half 2024 Hypertension Data Readout

Summary Mineralys Therapeutics, Inc. has two ongoing studies evaluating use of lorundrostat for the treatment of patients with uncontrolled or resistant hypertension; these are ADVANCE-HTN and LAUNCH-HTN. Results from the phase 3 ADVANCE-HTN study using lorundrostat for the treatment of patients with uncontrolled or resistant hypertension, expected in the 2nd half of 2024. Mineralys is also conducting a phase 2 study for the use of lorundrostat in treating hypertension in Chronic Kidney Disease patients, with results expected in the first half of 2024 or Q1 2025. The global hypertension market is expected to reach $43.18 billion by 2030. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Jon Congleton's remuneration changed compared to Mineralys Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$152m

Dec 31 2025US$6mUS$637k

-US$155m

Sep 30 2025n/an/a

-US$171m

Jun 30 2025n/an/a

-US$191m

Mar 31 2025n/an/a

-US$189m

Dec 31 2024US$5mUS$580k

-US$178m

Sep 30 2024n/an/a

-US$153m

Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$91m

Dec 31 2023US$5mUS$517k

-US$72m

Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$40m

Mar 31 2023n/an/a

-US$35m

Dec 31 2022US$2mUS$417k

-US$30m

Sep 30 2022n/an/a

-US$28m

Dec 31 2021US$675kUS$346k

-US$19m

Compensation vs Market: Jon's total compensation ($USD5.54M) is about average for companies of similar size in the US market ($USD5.30M).

Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.

CEO

Jon Congleton (63 yo)

5.6yrs
Tenure
US$5,544,727
Compensation

Dr. Jon Congleton has been an Independent Director of Avalyn Pharma Inc. since April 2026. He is Independent Director of Immunic, Inc. from March 27, 2026. Mr. Congleton serves as President, Chief Executiv...

Leadership Team

NamePositionTenureCompensationOwnership
Jon Congleton
President5.6yrsUS$5.54m0.66%
$ 13.1m
Brian Slingsby
Founder & Executive Director7.1yrsUS$247.04kno data
Adam Levy
CFO & Secretary4.3yrsUS$2.20m0.010%
$ 206.6k
David Rodman
Chief Medical Officer5.4yrsUS$2.20m0.077%
$ 1.5m
Jeffrey Munsie
Chief Legal Officerless than a yearno datano data
Robert McKean
Senior Vice President of CMCno datano datano data
Danielle Mahoney
Senior Vice President of Quality Assuranceno datano datano data
Jessica Ibbitson
Executive Vice President of Operations3.4yrsno datano data
Eric Warren
Chief Commercial Officer1.2yrsno data0.047%
$ 918.6k
Tiffany Burt
Senior Vice President of Medical Affairs1.4yrsno datano data
Michael Tortorici
Senior Vice President of Translational Medicine1.4yrsno datano data
Jose Breton
Senior VP of Finance & Controllerno datano datano data
3.4yrs
Average Tenure
49yo
Average Age

Experienced Management: MLYS's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jon Congleton
President5.6yrsUS$5.54m0.66%
$ 13.1m
Brian Slingsby
Founder & Executive Director7.1yrsUS$247.04kno data
Glenn Sblendorio
Independent Chairman2.8yrsUS$331.31k0%
$ 0
Srinivas Akkaraju
Independent Director5.3yrsUS$292.93kno data
Daphne Karydas
Independent Director2.8yrsUS$307.04k0.0075%
$ 148.4k
Alexander Gold
Independent Director2yrsUS$305.28kno data
Matthew Weir
Member of Scientific Advisory Boardno datano datano data
Derek DiRocco
Independent Director4.1yrsUS$304.54k0%
$ 0
James Luther
Member of Scientific Advisory Boardno datano datano data
Annet Kirabo
Member of Scientific Advisory Boardno datano datano data
Jennifer Green
Member of Scientific Advisory Boardno datano datano data
Reena Mehra
Member of Scientific Advisory Boardno datano datano data
4.1yrs
Average Tenure
58yo
Average Age

Experienced Board: MLYS's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/16 05:55
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mineralys Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Umer RaffatEvercore ISI
Richard J. LawGoldman Sachs